The Potential Benefits of Biofield Energy Treated Vitamin D3 on Bone Mineralization in Human Bone Osteosarcoma Cells (MG-63)

Permalink
https://escholarship.org/uc/item/4wg95066

Journal
International Journal of Nutrition and Food Sciences, 7(1)

ISSN
2327-2694 (Print); 2327-2716 (Online)

Authors
Lee, Aileen Carol
Trivedi, Mahendra Kumar
Branton, Alice
et al.

Publication Date
2018-01-17

DOI
10.11648/j.ijnfs.20180701.15

Peer reviewed
The Potential Benefits of Biofield Energy Treated Vitamin D₃ on Bone Mineralization in Human Bone Osteosarcoma Cells (MG-63)

Aileen Carol Lee¹, Mahendra Kumar Trivedi¹, Alice Branton¹, Dahryn Trivedi¹, Gopal Nayak¹, Sambhu Charan Mondal², Snehasis Jana²,*

¹Trivedi Global, Inc., Henderson, USA
²Trivedi Science Research Laboratory Pvt. Ltd., Bhopal, India

Email address:
publication@trivedisrl.com (S. Jana)
*Corresponding author

To cite this article:
Aileen Carol Lee, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana. The Potential Benefits of Biofield Energy Treated Vitamin D₃ on Bone Mineralization in Human Bone Osteosarcoma Cells (MG-63). International Journal of Nutrition and Food Sciences. Vol. 7, No. 1, 2018, pp. 30-38. doi: 10.11648/j.ijnfs.20180701.15

Received: November 28, 2017; Accepted: December 14, 2017; Published: January 17, 2018

Abstract: The study was aimed to evaluate the potential of Consciousness Energy Healing based vitamin D₃ and DMEM medium on bone health. The test items, were divided into two parts. One part of each sample received the Consciousness Energy Healing Treatment by Aileen Carol Lee and those samples were labeled as the Biofield Energy Treated (BT) samples, while the other parts of each sample were denoted as the untreated test items (UT). ALP, collagen, and bone mineralization activities were performed to assess bone health in human bone osteosarcoma cells (MG-63). The cell viability assay (MTT) data showed that the test samples were found as safe in the tested concentrations. The level of ALP was significantly increased by 251.16%, 103.75%, and 119.55% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item, respectively at 50 µg/mL, while 123.37% increased in the BT-DMEM + UT-Test item at 0.1 µg/mL compared to the UT-DMEM + UT-Test item group. Further, the ALP level was significantly elevated by 194.1%, 72.34%, and 65.31% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 100 µg/mL compared to the untreated group. Collagen was significantly increased by 83.02%, 145.67%, and 191.41% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 0.1 µg/mL compared to the untreated group. Further, the collagen level was significantly increased by 50.29% and 52.48% in the UT-DMEM + BT-Test item and BT-DMEM + BT-Test item, respectively at 50 µg/mL compared to the untreated group. Additionally, the percent of bone mineralization was distinctly increased by 64.46% and 94.16% in the UT-DMEM + BT-Test item and BT-DMEM + UT-Test item groups, respectively at 100 µg/mL compared to the untreated group. The percent of bone mineralization was distinctly increased by 26.59% and 28.33% in the BT-DMEM + UT-Test item group at 10 and 50 µg/mL, respectively compared to the UT-DMEM + UT-Test item group. Overall, the Biofield Energy Treated vitamin D₃ was remarkably improved the bone health parameters and it could be a powerful alternative nutraceutical supplement to combat vitamin D₃ deficiency and fight against various bone related problems including low bone density, osteoporosis, osteogenesis imperfecta, rickets, osteomalacia, bone and joint pain, bone fractures, deformed bones, osteoma, chondrodystrophia fetalis, autoimmune and inflammatory diseases, stress management and prevention, and anti-aging by improving overall health.

Keywords: The Trivedi Effect®, Osteosarcoma Cells (MG-63), Alizarin Red S Staining, ALP, Collagen, Bone Mineralization, Vitamin D₃ Deficiency, Low Bone Density
1. Introduction

Vitamin D has multiple effects, which regulate the functions in different organs viz. brain, liver, lungs, heart, kidneys, skeletal, immune and reproductive systems. Moreover, it has significant anti-inflammatory, anti-aging, anti-stress, anti-arithmetic, anti-osteoporosis, anti-apoptotic, wound healing, anti-cancer, anti-psychotic and anti-fibrotic actions [1]. Vitamin D receptors are widely distributed in most of the body organs viz. brain, liver, heart, lungs, kidney, pancreas, large and small intestines, muscles, reproductive, nervous system, etc. Vitamin D receptors influence cell-to-cell communication, normal cell growth, cell differentiation, cell cycling and proliferation, hormonal balance, neurotransmission process, skin health, immune and cardiovascular functions. In any living vertebrates, vitamin D plays an important role in maintaining a healthy skeletal structure and is essential for bone health. Naturally, it is synthesized in the presence of sunlight in the skin [2]. Most foods do not contain any vitamin D, additionally now-a-days due to aging, use of sunscreen, and change of zenith angle of sun the production of vitamin D3 has reduced [3]. Increasing age is not only related to a decrease in bone marrow depression and muscle strength but is also associated with marked changes in the immune and inflammatory responses [4]. Deficiency of vitamin D3 causes metabolic bone diseases like osteomalacia and exacerbate osteoporosis, etc. [5]. The quality of life for menopausal women is one of the most critical health problem in the today world. Metabolic bone disorders like osteoporosis are mainly prevalent in post-menopausal women. Hormonal factors and rapid bone loss in post-menopausal women leads to an increased risk of fractures [6]. Hence, the serum calcium and alkaline phosphatase (ALP) levels in post-menopausal women are the main two vital biochemical markers of bone metabolism. However, bone-specific ALP is the most important marker for osteoblast differentiation [7]. Further, it is generally accepted that an increased calcium intake along with an adequate source of vitamin D is important for maintaining good bone health. Vitamin D also plays an important role in maintaining an adequate level of serum calcium and phosphorous. Therefore, vitamin D has a great impact in forming and maintaining strong bones [8, 9]. Bone strength depends on the quality, geometry, shape, microarchitecture, turnover, mineral content, and the collagen content. Collagen is the major structural protein responsible for bone calcification. In the aging state, the mechanical properties of the bones become impaired and the bones get fragile, that causes various clinical disorders associated with bone collagen abnormalities and bone fragility, such as osteogenesis imperfecta and osteoporosis [10, 11].

In recent years, several scientific reports and clinical trials have revealed the useful effects of Biofield Energy Treatments, which have shown to enhance immune function in cases of cervical cancer patients via therapeutic touch [12], massage therapy [13], etc. Complementary and Alternative Medicine (CAM) therapies are now rising as preferred models of treatment, among which Biofield Therapy (or Healing Modalities) is one approach that has been reported to have several benefits to enhance physical, mental and emotional human wellness. However, as per the data of 2012 from the National Health Interview Survey (NHIS), which indicated that the highest percentage (17.7%) of the Americans used dietary supplements as a complementary health approach as compared with other practices in past years. The National Center of Complementary and Integrative Health (NCCIH) has recognized and accepted Biofield Energy Healing as a CAM health care approach in addition to other therapies, medicines and practices such as natural products, deep breathing, yoga, Tai Chi, Qi Gong, chiropractic/osteopathic manipulation, meditation, massage, special diets, homeopathy, progressive relaxation, guided imagery, acupressure, acupuncture, relaxation techniques, hypnotherapy, healing touch, movement therapy, pilates, rolling structural integration, mindfulness, Ayurvedic medicine, traditional Chinese herbs and medicines, naturopathy, essential oils, aromatherapy, Reiki, and cranial sacral therapy. Human Biofield Energy has subtle energy that has the capacity to work in an effective manner [14]. CAM therapies have been practiced worldwide with reported clinical benefits in different health disease profiles [15]. This energy can be harnessed and transmitted by the experts into living and non-living things via the process of Biofield Energy Healing. Biofield Energy Treatment (The Trivedi Effect®) has been published in numerous peer-reviewed science journals with significant outcomes in many scientific fields such as cancer research [16, 17], microbiology [18-21], biotechnology [22, 23], pharmaceutical science [24-27], agricultural science [28-31], materials science [32-35], nutraceuticals [36, 37], skin health, human health and wellness.

Based on the literature information and importance of vitamin D3 on bone health, the authors sought to evaluate the impact of the Biofield Energy Treatment (The Trivedi Effect®) on the test samples (vitamin D3 and DMEM medium) for bone health activity with respect to the assessment of different bone health parameters like ALP, collagen content, and bone mineralization using standard assays in MG-63 cells.

2. Materials and Methods

2.1. Chemicals and Reagents

Fetal bovine serum (FBS) and Dulbecco’s Modified Eagle’s Medium (DMEM) were purchased from Life Technology, USA. Rutin hydrate was purchased from TCI, Japan, while vitamin D3 (denoted as test item) and L-ascorbic acid were obtained from Sigma-Aldrich, USA. Antibiotic solution (penicillin-streptomycin) was procured from HiMedia, India, while 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium) (MTT), Direct Red 80, and ethylene diamine tetra acetic acid (EDTA) were purchased from Sigma, USA. All the other chemicals used in this
experiment were analytical grade procured from India.

2.2. Cell Culture

The human bone osteosarcoma cell line, MG-63, was used as the test system in the present study. The MG-63 cell line was maintained under the DMEM growth medium for routine culture and supplemented with 10% FBS. Growth conditions were maintained as 37°C, 5% CO2 and 95% humidity and subcultured by trypsinisation followed by splitting the cell suspension into fresh flasks and supplementing with fresh cell growth medium. Three days before the start of the experiment (i.e., day -3), the growth medium of near-confluent cells was replaced with fresh phenol-free DMEM, supplemented with 10% charcoal dextran stripped FBS (CD-FBS) and 1% penicillin-streptomycin [38].

2.3. Experimental Design

The experimental groups consisted of cells in baseline control, vehicle control groups (0.05% DMSO with Biofield Energy Treated and untreated DMEM), a positive control group (rutin hydrate) and experimental test groups. Experimental groups included the combination of the Biofield Energy Treated and untreated vitamin D3/DMEM. It consisted of four major treatment groups on specified cells with UT-DMEM + UT-Test item, UT-DMEM + Biofield Energy Treated test item (BT-Test item), BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item.

2.4. Consciousness Energy Healing Treatment Strategies

The test item (vitamin D3) and DMEM were divided into two parts. One part each of the test item and DMEM were treated with the Biofield Energy (also known as The Trivedi Effect®) and coded as the Biofield Energy Treated items, while the second part did not receive any sort of treatment and was defined as the untreated samples. This Biofield Energy Healing Treatment was provided by Aileen Carol Lee, who participated in this study and performed the Biofield Energy Treatment remotely for ~5 minutes. Aileen Carol Lee was remotely located in the USA, while the test samples were located in the research laboratory of Dabur Research Foundation, New Delhi, India. The Biofield Energy Treatment was administered for 5 minutes through the healer’s unique Energy Transmission process remotely to the test samples under laboratory conditions. Aileen Carol Lee in this study, never visited the laboratory in person, nor had any contact with the test item and medium. Further, the control group was treated with a sham healer for comparative purposes. The sham healer did not have any knowledge about the Biofield Energy Treatment. After that, the Biofield Energy Treated and untreated samples were kept in similar sealed conditions for experimental study.

2.5. Determination of Non-Cytotoxic Concentration

The cell viability test was performed by MTT assay in the human bone osteosarcoma cell line (MG-63). The cells were counted and plated in 96 well plates at the density corresponding to 5 X 10^3 to 10 X 10^3 cells/well/180 µL of cell growth medium. The above cells were incubated overnight under growth conditions and allowed cell recovery and exponential growth, then they were subjected to serum stripping or starvation. The cells were treated with the test item, DMEM, and the positive control. The untreated cells served as baseline control. The cells in the above plate(s) were incubated for a time point ranging from 24 to 72 hours in CO2 incubator at 37°C, 5% CO2 and 95% humidity. Following incubation, the plates were taken out and 20 µL of 5 mg/mL of MTT solution was added to all the wells followed by an additional incubation for 3 hours at 37°C. The supernatant was aspirated and 150 µL of DMSO and was added to each well to dissolve formazan crystals. The absorbance of each well was read at 540 nm using a Synergy HT micro plate reader, BioTek, USA. The percentage cytotoxicity at each tested concentration of the test substance was calculated using the following Equation 1:

\[
\% \text{ Cytotoxicity} = \left(\frac{(1-X)}{R}\right) \times 100
\]

Where, \(X\) = Absorbance of treated cells; \(R\) = Absorbance of untreated cells

The percentage cell viability corresponding to each treatment was then be obtained using the following Equation 2:

\[
\% \text{ Cell Viability} = 100 - \% \text{ Cytotoxicity}
\]

The concentrations exhibiting ≥70% Cell viability was considered as non-cytotoxic [39].

2.6. Assessment of Alkaline Phosphatase (ALP) Activity

The cells were counted using an hemocytometer and plated in a 24-well plate at the density corresponding 1 x 10^4 cells/well in phenol free DMEM supplemented with 10% CD-FBS. Following the respective treatments, the cells in the above plate were incubated for 48 hours in CO2 incubator at 37°C, 5% CO2 and 95% humidity. After 48 hours of incubation, the plate was taken out and processed for the measurement of ALP enzyme activity. The cells were washed with 1X PBS and lysed by freeze thaw method i.e., incubation at -80°C for 20 minutes followed by incubation at 37°C for 10 minutes. To the lysed cells, 50 µL of substrate solution \(i.e., \) 5 mM of \(p\)-nitrophenyl phosphate (\(p\)NPP) in 1M diethanolamine and 0.24 mM magnesium chloride (\(\text{MgCl}_2\)) solution (pH 10.4) was added to all the wells followed by incubation for 1 hour at 37°C. The absorbance of the above solution was read at 405 nm using Synergy HT micro plate reader (Biotek, USA). The absorbance values obtained were normalized with substrate blank (\(p\)NPP solution alone) absorbance values. The percentage increase in ALP enzyme activity with respect to the untreated cells (baseline group) was calculated using Equation 3:

\[
\% \text{ Increase in ALP} = \left(\frac{(X-R)}{R}\right) \times 100
\]

Where, \(X\) = Absorbance of cells corresponding to positive control and test groups
R = Absorbance of cells corresponding to baseline group (untreated cells)

2.7. Assessment of Collagen Synthesis

The MG-63 cells were counted using an hemocytometer and plated in 24-well plate at the density corresponding to 10 x 10³ cells/well in phenol free DMEM supplemented with 10% CD-FBS. Following the respective treatments, the cells in the above plate were incubated for 48 hours in CO₂ incubator at 37°C, 5% CO₂ and 95% humidity. After 48 hours of incubation, the plate was taken out and the amount of collagen accumulated in MG-63 cells corresponding to each treatment was measured by Direct Sirius red dye binding assay. In brief, the cell layers were washed with PBS and fixed in Bouin’s solution (5% acetic acid, 9% formaldehyde and 0.9% picric acid) for 1 hour at room temperature (RT). After 1 hour of incubation, the above wells were washed with milliQ water and air dried. The cells were then stained with Sirius red dye solution for 1 hour at RT followed by washing in 0.01 N HCl to remove unbound dye. The collagen dye complex obtained in the above step was dissolved in 0.1 N NaOH and absorbance was read at 540 nm using Biotek Synergy HT micro plate reader. The level of collagen was extrapolated using standard curve obtained from purified Calf Collagen Bornstein and Traub Type I (Sigma Type III). The percentage increase in collagen level with respect to the untreated cells (baseline group) was calculated using Equation 4:

% Increase in collagen levels = \{(X-R)/R\} * 100

Where, X = Collagen levels in cells corresponding to positive control and test groups
R = Collagen levels in cells corresponding to baseline (untreated cells)

2.8. Assessment of Bone Mineralization by Alizarin Red S Staining

The MG-63 cells were counted using an hemocytometer and plated in 24-well plate at the density corresponding to 10 x 10³ cells/well in phenol free DMEM supplemented with 10% CD-FBS. Following the respective treatments, the cells in the above plate were incubated for 48 hours in CO₂ incubator at 37°C, 5% CO₂ and 95% humidity to allow cell recovery and exponential growth. Following overnight incubation, the above cells were subjected to serum stripping for 24 hours. The cells were then treated with non-cytotoxic concentrations of the test samples and positive control. Following 3-7 days of incubation with the test samples and positive control, the plates were taken out, cell layers processed further by staining with Alizarin Red S dye. The cells were fixed in 70% ethanol for 1 hour, after which Alizarin Red solution (40 µm; pH 4.2) was added to the samples for 20 minutes with shaking. The cells were washed with distilled water to remove unbound dye. For quantitative analysis by absorbance evaluation, nodules were solubilized with 10% cetylpyridinium chloride for 15 minutes with shaking. Absorbance was measured at 562 nm using Biotek Synergy HT micro plate reader. The percentage increase in bone mineralization with respect to the untreated cells (baseline group) was calculated using the following Equation 5:

% Increase = \{(X-R)/R\} * 100

Where, X = Absorbance in cells corresponding to positive control or test groups; R = Absorbance in cells corresponding to baseline (untreated) group.

2.9. Statistical Analysis

All the values were represented as percentage of the respective parameters. For statistical analysis Sigma-Plot (version 11.0) was used as a statistical tool. Statistically significant values were set at the level of \(p \leq 0.05\).

3. Results and Discussion

3.1. MTT Assay

The cell viability data of the Biofield Energy Treated vitamin D₃ and DMEM by MTT assay in MG-63 cells are depicted in Figure 1. The data showed that the test samples in combination did not exhibit any cytotoxicity (as evidence of cell viability approximately greater than 73%) across all the tested concentrations up to 100 µg/mL. Hence, the same concentrations were assessed further to see the effect of the test samples on the levels of alkaline phosphatase (ALP) activity, collagen synthesis, and bone mineralization in MG-63 cells.

![Figure 1](image_url). The cell viability expressed as percentage of the test samples (vitamin D₃ and DMEM medium) in different concentrations in MG-63 cells after 72 hours of treatment. VC: Vehicle control (0.05% DMSO); UT: Untreated; BT: Biofield Energy Treated, TI: Test Item.
3.2. Alkaline Phosphatase (ALP) Activity

The effect of the Biofield Energy Treated test items on the level of alkaline phosphatase (ALP) in human bone osteosarcoma cells is presented in Figure 2. The level of ALP was found as 7.5% in the vehicle control (VC) group compared to the baseline control group. The ALP activity was significantly increased in a dose dependent manner by 34.31%, 51.47%, and 189.39% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at the concentration of 0.1 µg/mL compared to the UT-DMEM + UT-Test item group. Moreover, ALP activity was significantly increased by 23.38%, 123.37%, and 111.43% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 0.1 µg/mL compared to the UT-DMEM + UT-Test item group. Further, the level of ALP was significantly increased by 2.2% in the BT-DMEM + BT-Test item group, at the concentration of 10 µg/mL compared to the UT-DMEM + UT-Test item group. Further, the ALP level was significantly elevated by 194.1%, 72.34%, and 65.31% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 100 µg/mL compared to the UT-DMEM + UT-Test item group. Overall, the Consciousness Energy Healing Treated (The Trivedi Effect®) test item group (i.e., vitamin D3) showed an improved synthesis of ALP level in the human osteosarcoma cells with respect to the untreated items group. For bone formation and bone resorption, various biomarkers are now available for specific and sensitive assessment. For example, the bone formation biomarkers are total alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BALP), osteocalcin (OC), procollagen type 1 N-terminal propeptide (P1NP) and procollagen type 1 C-terminal propeptide (P1CP) [40, 6]. ALP is a group of cell membrane metalloenzymes that catalyze the hydrolysis of phosphate esters in an alkaline environment, generating an organic radical and inorganic phosphate. It is expressed mainly in bone, liver, intestines, proximal convoluted tubules of the kidney, and in the placenta and released from these tissues in the blood [41]. In this experiment, it was also evident that the Biofield Energy Treated vitamin D3 significantly increased the level of ALP expression, which might be very advantageous to maintain a healthy skeletal structure for the patients suffering from various bone related disorders.

Figure 2. The effect of the Biofield Energy Treated test samples on alkaline phosphatase enzyme activity in human bone osteosarcoma cells. VC: Vehicle control (0.05% DMSO), UT: Untreated; BT: Biofield Energy Treated, TI: Test Item.

3.3. Assessment of Collagen Activity

The effect of the test samples on the collagen content in human bone osteosarcoma cells is shown in Figure 3. Collagen level in the VC group was found as 13%. The level of collagen synthesis was significantly increased by 63.44%, 63.83%, and 79.45% at 0.01, 0.1, and 1 µg/mL, respectively in the positive control group compared to the untreated cells group. The level of collagen was significantly increased by 251.16%, 103.75%, and 119.55% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 10 µg/mL compared to the UT-DMEM + UT-Test item group. Further, collagen level was significantly increased by 40.40% in the BT-DMEM + BT-Test item group at 1 µg/mL compared to the UT-DMEM + UT-Test item group. The collagen synthesis was significantly increased by 14.12% and 31.79% in the BT-DMEM + BT-Test item and BT-DMEM + BT-Test item groups, respectively at 10 µg/mL compared to the UT-DMEM + UT-Test item group. Moreover, the collagen level was significantly increased by 194.1%, 72.34%, and 65.31% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 100 µg/mL compared to the UT-DMEM + UT-Test item group. Additionally, at 100 µg/mL the level of collagen was also significantly increased by 12.88%, 64.51%, and 71.50% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively
with respect to the UT-DMEM + UT-Test item group (Figure 3). Overall, the Consciousness Energy Healing based test item group (i.e., vitamin D3) showed an improved synthesis of collagen content in the human osteosarcoma cells with respect to all the treatment groups. Bones with sufficient collagen act as a steel like strong and elastic. Bones that are lack of collagen are like dry, brittle wood, easily broken. Type I collagen is the major structural protein in extra cellular matrix responsible for bone calcification. It also plays a vital role in further promoting osteoblast differentiation [42]. From literature it was reported that the dietary collagen peptides would effectively prevent age-related bone loss like osteogenesis imperfecta and osteoporosis, there was an abnormality of collagen synthesis, stability and maturation [43-47]. Overall, The Trivedi Effect® - Consciousness Energy Healing Treatment modality showed a significant improvement of the collagen level in human osteosarcoma cells. Thus, it is assumed that The Trivedi effect® has the potential to improve the bone health in various skeletal disorders.

![Image](image1.png)

**Figure 3.** The effect of the test samples on collagen activity in human bone osteosarcoma cells. VC: Vehicle control (0.05% DMSO), UT: Untreated; BT: Biofield Energy Treated, TI: Test Item.

### 3.4. Assessment of Bone Mineralization by Alizarin Red S (ARS) Staining

The Alizarin red S (ARS) staining is widely utilized for the assessment of calcium-rich deposits or calcium crystals in the cell culture study. Endocrine factors can strongly influenced to restore the balance between bone formation and resorption. Bone formation involves the mineralization of the extracellular matrix formed by osteoblasts. In this process vitamin D stimulates the bone mineralization of human osteoblasts but is often found inhibitory for mineralization of murine osteoblasts [48, 49]. The bone mineralization in human bone osteosarcoma cells is shown in Figure 4. The percentage of bone mineralization was distinctly increased by 26.59% in the BT-DMEM + UT-Test item group at 10 µg/mL compared to the UT-DMEM + UT-Test item group. Further, a noticeably increased percentage of bone mineralization by 28.33% in the BT-DMEM + UT-Test item group was observed at 50 µg/mL with respect to the UT-DMEM + UT-Test item group. In addition, the data showed a significant increase of bone mineralization by 64.46% and 94.16% in the UT-DMEM + BT-Test item and BT-DMEM + UT-Test item groups, respectively than the UT-DMEM + UT-Test item group (Figure 4) at 100 µg/mL. Thus, based on the above findings it is hypothesized that the Consciousness Energy Healing Treatment (The Trivedi Effect®) based test item groups (i.e., vitamin D₃) showed a remarkable improvement of bone mineralization content assessed by in vitro in the human osteosarcoma cells (MG-63) with respect to the all others treatment groups.

![Image](image2.png)

**Figure 4.** The effect of the Biofield Energy Treated test samples on human bone osteosarcoma cells for the assessment of bone mineralization activity. VC: Vehicle control (0.05% DMSO), UT: Untreated; BT: Biofield Energy Treated, TI: Test Item.
4. Conclusions

The MTT cell viability assay data showed more than 73% cells were viable, which indicated that the test samples were safe and nontoxic in all the tested concentrations. ALP was significantly increased by 251.16%, 103.75%, and 119.55% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item, respectively at 100 µg/mL compared to the untreated group. Further, the percent of bone mineralization was distinctly increased by 64.46% and 94.16% in the UT-DMEM + BT-Test item and BT-DMEM + UT-Test item groups, respectively at 100 µg/mL compared to the untreated group. Altogether, the Biofield Energy Treated test samples (The Trivedi Effect®) demonstrated a significant impact on bone health parameters. Therefore, the Consciousness Energy Healing based vitamin D3 might be suitable for the development of an alternative and more effective supplement for vitamin D3 deficiency, which could be useful for the management of various bone related disorders viz. low bone density and osteoporosis, osteogenesis imperfecta, Paget’s disease of bone, rickets, osteomalacia, bone and joint pain, bone fractures, deformed bones, osteoma, chondrodystrophy fetalis, etc. Besides, it can also be utilized in organ transplants (for example kidney transplants, liver transplants and heart transplants), various autoimmune disorders such as Lupus, Addison Disease, Celiac Disease (gluten-sensitive enteropathy), Dermatomyositis, Graves’ Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Aplastic Anemia, Reactive Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Type 1 Diabetes, Alopecia Areata, Crohn’s Disease, Fibromyalgia, Vitiligo, Psoriasis, Scleroderma, Chronic Fatigue Syndrome and Vasculitis, as well as inflammatory disorders such as Asthma, Ulcerative Colitis, Alzheimer’s Disease, Atherosclerosis, Dermatitis, Diverticulitis, Hepatitis, Irritable Bowel Syndrome, inflammatory diseases, anti-inflammatory, anti-stress, anti-arthritis, anti-osteoporosis, anti-apoptotic, wound healing, anti-cancer, anti-psychotic and anti-fibrotic actions stress management and prevention, and anti-aging by improving overall health, Parkinson’s Disease and stress etc. to modulate the immune system by improving overall health.

Abbreviations

MG-63: Human Bone Osteosarcoma Cells, ALP: Alkaline phosphatase, CAM: Complementary and alternative medicine, NHIS: National Health Interview Survey, NCCIH: National Center of Complementary and Integrative Health, DMEM: Dulbecco’s modified eagle’s medium, FBS: Fetal bovine serum, ATCC: American type culture collection, UT: Untreated, BT: Biofield Energy Treated, AGE: Advanced glycation end products.

Acknowledgements

Authors are grateful to Dabur Research Foundation, Trivedi Global, Inc., Trivedi Science, Trivedi Testimonials and Trivedi Master Wellness for their support throughout the work.

References

[1] Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases cancers, and cardiovascular disease. Am J Clin Nut 80: 1678S-1688S.
[2] Holick MF (1996) Vitamin D and bone health. J Nutr 126: 1159S-1164S.
[3] Matsuoka LY, Ide L, Wortsman J, Mac Laughlin JA, Holick MF (1987) Sunscreens suppress vitamin D3 synthesis. J Clin Endocrinol Metab 64: 1165-1168.
[4] Barnes MS, Robson JP, Bonham MP, Strain J, Wallace J (2006) Vitamin D: Status, supplementation and immunodulation. Cur Nut Food Sci 2: 315-336.
[5] Laird E, Ward M, McSorley E, Strain J, Wallace J (2010) Vitamin D and bone health; Potential mechanisms. Nutrients 2: 693-724.
[6] Bhattacharyya K, Chaudhuri P, Sengupta P (2015) Correlation of common biochemical markers for bone turnover, serum calcium, and alkaline phosphatase in post-menopausal women. The Malaysian Journal of Medical Sciences : MJMS 21: 58-61.
[7] Iba K, Takada J, Yamashita T (2004) The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients. J Bone Miner Metab 22: 594-596.
[8] Holick MF, Garabedian M (2006) Vitamin D: Photobiology, metabolism, mechanism of action, and clinical applications. Primer on the metabolic bone diseases and disorders of mineral metabolism. Edited by: Favus MJ, Washington, DC.
[9] DeLuca HF (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80: 1689S-1696S.
[10] Viguet-Carrin S, Gamero P, Delmas PD (2006) The role of collagen in bone strength. Osteoporos Int 17: 319-336.
[11] Sroga GE, Vashishth D (2012) Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr Osteoporos Rep 10: 141-150.
[12] Lutgendorf SK, Muller-Hoer E, Russell D, Degeest K, Jacobson G, Hart L, Bender D, Anderson B, Buckers TE, Goodheart MJ, Antoni MH, Sood AK, Lubaroff DM (2010) Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav and Immun 24: 1231-1240.
[13] Ironson G, Field T, Scafidi F, Hashimoto M, Kumar M, Kumar A, Price A, Goncalves A, Burman I, Tettenen C, Patarca R, Fletcher MA (1996) Massage therapy is associated with enhancement of the immune system's cytotoxic capacity. Int J Neurosci 84: 205-217.

[14] Jain S, Hammerschlag R, Mills P, Cohen L, Krieger R, Vieten C, Lutgendorf S (2015) Clinical studies of biofield therapies: Summary, methodological challenges, and recommendations. Glob Adv Health Med 4: 58-66.

[15] Rubik B (2002) The biofield hypothesis: Its biophysical basis and role in medicine. J Altern Complement Med 8: 703-717.

[16] Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) The potential impact of biofield treatment on human brain tumor cells: A time-lapse video microscopy. J Integr Oncol 4: 141.

[17] Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) In vitro evaluation of biofield treatment on cancer biomarkers involved in endometrial and prostate cancer cell lines. J Cancer Sci Ther 7: 253-257.

[18] Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) In vitro evaluation of biofield treatment on Enterobacter cloacae: Impact on antimicrobial susceptibility and biotype. J Bacteriol Parasitol 6: 241.

[19] Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) Evaluation of biofield modality on viral load of hepatitis B and C Viruses. J Antivir Antiretrovir 7: 083-088.

[20] Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) An impact of biofield treatment: Antimycobacterial susceptibility potential using BACTEC 460/MGIT-TB System. Mycobiol Dis 5: 189.

[21] Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S (2015) Antimicrobial sensitivity, biochemical characteristics and biotyping of Staphylococcus saprophyticus: An impact of biofield energy treatment. J Women’s Health Care 4: 271.

[22] Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S (2015) Evaluation of antibiogram, genotype and phylogenetic analysis of biofield treated Nocardia otitidis. Bio Syst Open Access 4: 143.

[23] Trivedi MK, Branton A, Trivedi D, Nayak G, Charan S, Jana S (2015) Phenotyping and 16S rDNA analysis after biofield treatment on Citrobacter braakii: A urinary pathogen. J Clin Med Genom 3: 129.

[24] Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Spectroscopic characterization of chloramphenicol and tetracycline: An impact of biofield. Pharm Anal Acta 6: 395.

[25] Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Spectroscopic characterization of biofield treated metronidazole and tinidazole. Med Chem 5: 340-344.

[26] Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Effect of biofield treatment on spectral properties of paracetamol and piroxicam. Chem Sci J 6: 98.

[27] Trivedi MK, Branton A, Trivedi D, Shettigar H, Bairwa K, Jana S (2015) Fourier transform infrared and ultraviolet-visible spectroscopic characterization of biofield treated salicylic acid and sparfloxacin. Nat Prod Chem Res 3: 186.

[28] Trivedi MK, Branton A, Trivedi D, Nayak G, Gangwar M, Jana S (2016) Molecular analysis of biofield treated eggplant and watermelon crops. Adv Crop Sci Tech 4: 208.

[29] Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S (2015) Morphological characterization, quality, yield and DNA fingerprinting of biofield energy treated alphonso mango (Mangifera indica L.). Journal of Food and Nutrition Sciences 3: 245-250.

[30] Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S (2015) Evaluation of plant growth, yield and yield attributes of biofield energy treated mustard (Brassica juncea) and chick pea (Cicer arietinum) seeds. Agriculture, Forestry and Fisheries 4: 291-295.

[31] Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, Jana S (2015) Evaluation of plant growth regulator, immunity and DNA fingerprinting of biofield energy treated mustard seeds (Brassica juncea). Agriculture, Forestry and Fisheries 4: 269-274.

[32] Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, Jana S (2015) Characterization of physical and structural properties of aluminium carbide powder: Impact of biofield treatment. J Aeronaut Aerospace Eng 4: 142.

[33] Trivedi MK, Nayak G, Patil S, Tallapragada RM, Latiyal O, Jana S (2015) Impact of biofield treatment on atomic and structural characteristics of barium titanate powder. Ind Eng Manage 4: 166.

[34] Trivedi MK, Patil S, Nayak G, Jana S, Latiyal O (2015) Influence of biofield treatment on physical, structural and spectral properties of boron nitride. J Material Sci Eng 4: 181.

[35] Trivedi MK, Nayak G, Patil S, Tallapragada RM, Latiyal O, Jana S (2015) Characterization of physical and structural properties of brass powder after biofield treatment. J Powder Metall Min 4: 134.

[36] Trivedi MK, Nayak G, Patil S, Tallapragada RM, Jana S, Mishra RK (2015) Bio-field treatment: An effective strategy to improve the quality of beef extract and meat infusion powder. J Nutr Food Sci 5: 389.

[37] Trivedi MK, Tallapragada RM, Branton A, Trivedi D, Nayak G, Mishra RK, Jana S (2015) Biofield treatment: A potential strategy for modification of physical and thermal properties of gluten hydrolysate and ipomoea macroelomers. J Nutr Food Sci 5: 414.

[38] Czekanska EM, Stoddart MJ, Richards RG, Hayes JS (2012) In search of an osteoblast cell model for in vitro research. Eur Cells Mater 24: 1-17.

[39] Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity (ISO 10993-5: 2009), I. S. EN ISO, 10993-5: 20093.

[40] Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan I, Comm Sci Advisors Int O. (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11: 2-17.

[41] Warnes TW (1972) Alkaline phosphatase. Gut 13: 926-937.

[42] Oishi Y, Fu ZW, Ohnuki Y, Kato H, Noguchi T (2002) Molecular basis of the alteration in skin collagen metabolism in response to dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 147: 859-868.
Takeuchi Y, Nakayama K, Matsumoto T (1996) Differentiation and cell surface expression of transforming growth factor-beta receptors are regulated by interaction with matrix collagen in murine osteoblastic cells. J Biol Chem 271: 3938-3944.

Adam M, Spacek P, Hulejová H, Galiánová A, Blahos J (1996) Postmenopausal osteoporosis. Treatment with calcitonin and a diet rich in collagen proteins. Cas Lek Cesk 135: 74-78.

Viguet-Carrin S, Gamero P, Delmas PD (2005) The role of collagen in bone strength. Osteoporos Int 17: 319-336.

Viguet-Carrin S, Roux JP, Arlot ME, Merabet Z, Leeming DJ, Byrjalsen I, Delmas PD, Bouxsein ML (2006) Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 39: 1073-1079.

Mechanic GL, Toverud SU, Ramp WK, Gonnerman WA (1975) The effect of vitamin D on the structural crosslinks and maturation of chick bone collagen. Biochim Biophys Acta 393: 419-425.

Van Driel M, van Leeuwen JPTM (2017) Vitamin D endocrinology of bone mineralization. Mol Cell Endocrinol 453: 46-51.

Van Leeuwen JP, van Driel M, van den Bermd GJ, Pols HA (2001) Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr 11: 199-226.